Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Breast Cancer
Docetaxel regimen for early stage breast cancer significantly improves survival
January 13th, 2005
Aventis announced that the results of a phase 3 study demonstrated that Taxotere (docetaxel) Injection Concentrate-based regimen improved overall survival of women with operable, node-positive early stage breast cancer compared to a standard regimen of 5-fluorouracil, epirubicin, and cyclophosphamide (FEC-100). These data were disclosed during an oral presentation at the 27th Charles A. Coltman, Jr. San Antonio Breast Cancer Symposium (SABCS). The trial, PACS 01, conducted by investigators from the Federation National des Centres de Lutte contre le Cancer (FNCLCC) in France, showed that women with operable, node-positive, early stage breast cancer...
Source: Women's Health Weekly (2005-01-13)
|
